Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239666 · ClinicalTrials.gov registry record
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 899
- Enrollment target
NCT02239666: Completed study, sponsored by AstraZeneca.
NCT02239666 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 899 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02239666 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 899 participants
- Enrollment target
Study Summary
To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.
Primary Outcome
Physician-completed Psoriasis Area and Severity Index (PASI) measuring for each study subject average redness, thickness and scaliness of plaque psoriasis regions, weighted by area of involvement in each of four regions (head and neck, upper extremities, trunk, lower extremities). PASI100 represents a 100% improvement from baseline, that is, complete clearance. A static, or one-off, PASI (sPASI) score of 0 is equivalent to PASI100
Interventions
- OTHER NIS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 899 participants |
| Start Date | 2014-03-01 |
| Est. Completion | 2017-01-05 |
What the finished NCT02239666 record still lists
NCT02239666 is an observational study that tracks outcomes without assigning an intervention. The registered 899 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which NIS is the first listed.
NCT02239666 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02239666 about?
NCT02239666 is a clinical study titled "Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis". To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.
What is the current status of trial NCT02239666?
This trial is currently completed. The enrollment target is 899 participants. The study started on 2014-03-01. Estimated completion is 2017-01-05.
What interventions are being tested in trial NCT02239666?
The interventions under investigation include: NIS (OTHER).
Who is sponsoring clinical trial NCT02239666?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI